6月2日，Abivax S.A.盘前下跌30.12%，报88.88美元/股，成交额179.2万美元。
消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽然试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但有报道称试验数据因癌症病例而变得复杂，市场对安全性数据反应强烈消极。此前纳斯达克交易所因消息未披露对该股实施停牌，恢复交易后股价即遭大幅抛售，反映投资者对药物安全性风险的重新定价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.